Public Meeting of the Presidential Commission for the Study of Bioethical Issues, 41789 [2012-17313]

Download as PDF Federal Register / Vol. 77, No. 136 / Monday, July 16, 2012 / Notices background material on its Web site prior to the meeting, it will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on ONC’s Web site after the meeting, at https://healthit.hhs.gov. Procedure: ONC is committed to the orderly conduct of its advisory committee meetings. Interested persons may present data, information, or views, orally or in writing, on issues pending before the Committee. Written submissions may be made to the contact person on or before two days prior to the Committee’s meeting date. Oral comments from the public will be scheduled in the agenda. Time allotted for each presentation will be limited to three minutes. If the number of speakers requesting to comment is greater than can be reasonably accommodated during the scheduled public comment period, ONC will take written comments after the meeting until close of business on that day. Persons attending ONC’s advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets. ONC welcomes the attendance of the public at its advisory committee meetings. Seating is limited at the location, and ONC will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact MacKenzie Robertson at least seven (7) days in advance of the meeting. Notice of this meeting is given under the Federal Advisory Committee Act (Pub. L. 92–463, 5 U.S.C., App. 2). Dated: July 5, 2012. MacKenzie Robertson, FACA Program Lead, Office of Policy and Planning, Office of the National Coordinator for Health Information Technology. [FR Doc. 2012–17288 Filed 7–13–12; 8:45 am] BILLING CODE 4150–45–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Meeting of the Presidential Commission for the Study of Bioethical Issues Department of Health and Human Services, Office of the Assistant Secretary for Health, Presidential Commission for the Study of Bioethical Issues. ACTION: Notice of meeting. srobinson on DSK4SPTVN1PROD with NOTICES AGENCY: The Presidential Commission for the Study of Bioethical Issues will conduct its tenth meeting in August. At SUMMARY: VerDate Mar<15>2010 16:32 Jul 13, 2012 Jkt 226001 this meeting, the Commission will continue discussing topics related to the ethical issues associated with the development of medical countermeasures for children. The Commission will also develop and finalize recommendations regarding access to, and privacy of human genome sequence data. DATES: The meeting will take place Wednesday and Thursday, August 1–2, 2012. ADDRESSES: Renaissance Washington, DC Downtown Hotel, 999 9th Street NW., Washington, DC 20001. Telephone (202) 898–9000. FOR FURTHER INFORMATION CONTACT: Hillary Wicai Viers, Communications Director, Presidential Commission for the Study of Bioethical Issues, 1425 New York Avenue NW., Suite C–100, Washington, DC 20005. Telephone: 202–233–3960. Email: Hillary.Viers@bioethics.gov. Additional information may be obtained at www.bioethics.gov. SUPPLEMENTARY INFORMATION: Pursuant to the Federal Advisory Committee Act of 1972, Public Law 92–463, 5 U.S.C. app. 2, notice is hereby given of the tenth meeting of the Presidential Commission for the Study of Bioethical Issues (the Commission). The meeting will be held from 9 a.m. to approximately 5:30 p.m. on Wednesday, August 1, 2012, and from 9 a.m. to approximately 4 p.m. on Thursday, August 2, 2012, in Washington, DC. The meeting will be open to the public with attendance limited to space available. The meeting will also be webcast at www.bioethics.gov. Under authority of Executive Order 13521, dated November 24, 2009, the President established the Commission. The Commission is an advisory panel of the nation’s leaders in medicine, science, ethics, religion, law, and engineering. The Commission advises the President on bioethical issues arising from advances in biomedicine and related areas of science and technology. The Commission seeks to identify and promote policies and practices that ensure scientific research, health care delivery, and technological innovation are conducted in a socially and ethically responsible manner. The main agenda item for the Commission’s tenth meeting is to continue discussing topics related to the ethical issues associated with the development of medical countermeasures for children. The Commission will also develop and finalize recommendations regarding access to, and privacy of human genome sequence data. PO 00000 Frm 00049 Fmt 4703 Sfmt 9990 41789 The draft meeting agenda and other information about PCSBI, including information about access to the webcast, will be available at www.bioethics.gov. The Commission welcomes input from anyone wishing to provide public comment on any issue before it. Respectful debate of opposing views and active participation by citizens in public exchange of ideas enhances overall public understanding of the issues at hand and conclusions reached by the Commission. The Commission is particularly interested in receiving comments and questions during the meeting that are responsive to specific sessions. Written comments will be accepted at the registration desk and comment forms will be provided to members of the public in order to write down questions and comments for the Commission as they arise. To accommodate as many individuals as possible, the time for each question or comment may be limited. If the number of individuals wishing to pose a question or make a comment is greater than can reasonably be accommodated during the scheduled meeting, the Commission may make a random selection. Anyone planning to attend the meeting who needs special assistance, such as sign language interpretation or other reasonable accommodations, should notify Esther Yoo by telephone at (202) 233–3960, or email at Esther.Yoo@bioethics.gov in advance of the meeting. The Commission will make every effort to accommodate persons who need special assistance. Written comments will also be accepted in advance of the meeting and are especially welcome. Please address written comments by email to info@bioethics.gov, or by mail to the following address: Public Commentary, Presidential Commission for the Study of Bioethical Issues, 1425 New York Ave. NW., Suite C–100, Washington, DC 20005. Comments will be publicly available, including any personally identifiable or confidential business information that they contain. Trade secrets should not be submitted. Dated: July 9, 2012. Lisa M. Lee, Executive Director, Presidential Commission for the Study of Bioethical Issues. [FR Doc. 2012–17313 Filed 7–13–12; 8:45 am] BILLING CODE 4154–06–P E:\FR\FM\16JYN1.SGM 16JYN1

Agencies

[Federal Register Volume 77, Number 136 (Monday, July 16, 2012)]
[Notices]
[Page 41789]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-17313]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES


Public Meeting of the Presidential Commission for the Study of 
Bioethical Issues

AGENCY: Department of Health and Human Services, Office of the 
Assistant Secretary for Health, Presidential Commission for the Study 
of Bioethical Issues.

ACTION: Notice of meeting.

-----------------------------------------------------------------------

SUMMARY: The Presidential Commission for the Study of Bioethical Issues 
will conduct its tenth meeting in August. At this meeting, the 
Commission will continue discussing topics related to the ethical 
issues associated with the development of medical countermeasures for 
children. The Commission will also develop and finalize recommendations 
regarding access to, and privacy of human genome sequence data.

DATES: The meeting will take place Wednesday and Thursday, August 1-2, 
2012.

ADDRESSES: Renaissance Washington, DC Downtown Hotel, 999 9th Street 
NW., Washington, DC 20001. Telephone (202) 898-9000.

FOR FURTHER INFORMATION CONTACT: Hillary Wicai Viers, Communications 
Director, Presidential Commission for the Study of Bioethical Issues, 
1425 New York Avenue NW., Suite C-100, Washington, DC 20005. Telephone: 
202-233-3960. Email: Hillary.Viers@bioethics.gov. Additional 
information may be obtained at www.bioethics.gov.

SUPPLEMENTARY INFORMATION: Pursuant to the Federal Advisory Committee 
Act of 1972, Public Law 92-463, 5 U.S.C. app. 2, notice is hereby given 
of the tenth meeting of the Presidential Commission for the Study of 
Bioethical Issues (the Commission). The meeting will be held from 9 
a.m. to approximately 5:30 p.m. on Wednesday, August 1, 2012, and from 
9 a.m. to approximately 4 p.m. on Thursday, August 2, 2012, in 
Washington, DC. The meeting will be open to the public with attendance 
limited to space available. The meeting will also be webcast at 
www.bioethics.gov.
    Under authority of Executive Order 13521, dated November 24, 2009, 
the President established the Commission. The Commission is an advisory 
panel of the nation's leaders in medicine, science, ethics, religion, 
law, and engineering. The Commission advises the President on 
bioethical issues arising from advances in biomedicine and related 
areas of science and technology. The Commission seeks to identify and 
promote policies and practices that ensure scientific research, health 
care delivery, and technological innovation are conducted in a socially 
and ethically responsible manner.
    The main agenda item for the Commission's tenth meeting is to 
continue discussing topics related to the ethical issues associated 
with the development of medical countermeasures for children. The 
Commission will also develop and finalize recommendations regarding 
access to, and privacy of human genome sequence data.
    The draft meeting agenda and other information about PCSBI, 
including information about access to the webcast, will be available at 
www.bioethics.gov.
    The Commission welcomes input from anyone wishing to provide public 
comment on any issue before it. Respectful debate of opposing views and 
active participation by citizens in public exchange of ideas enhances 
overall public understanding of the issues at hand and conclusions 
reached by the Commission. The Commission is particularly interested in 
receiving comments and questions during the meeting that are responsive 
to specific sessions. Written comments will be accepted at the 
registration desk and comment forms will be provided to members of the 
public in order to write down questions and comments for the Commission 
as they arise. To accommodate as many individuals as possible, the time 
for each question or comment may be limited. If the number of 
individuals wishing to pose a question or make a comment is greater 
than can reasonably be accommodated during the scheduled meeting, the 
Commission may make a random selection.
    Anyone planning to attend the meeting who needs special assistance, 
such as sign language interpretation or other reasonable 
accommodations, should notify Esther Yoo by telephone at (202) 233-
3960, or email at Esther.Yoo@bioethics.gov in advance of the meeting. 
The Commission will make every effort to accommodate persons who need 
special assistance.
    Written comments will also be accepted in advance of the meeting 
and are especially welcome. Please address written comments by email to 
info@bioethics.gov, or by mail to the following address: Public 
Commentary, Presidential Commission for the Study of Bioethical Issues, 
1425 New York Ave. NW., Suite C-100, Washington, DC 20005. Comments 
will be publicly available, including any personally identifiable or 
confidential business information that they contain. Trade secrets 
should not be submitted.

    Dated: July 9, 2012.
Lisa M. Lee,
Executive Director, Presidential Commission for the Study of Bioethical 
Issues.
[FR Doc. 2012-17313 Filed 7-13-12; 8:45 am]
BILLING CODE 4154-06-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.